Literature DB >> 27416887

Pharmacokinetics of oral fludrocortisone in septic shock.

Andrea Polito1,2, Noureddine Hamitouche3,4, Mégane Ribot2,5, Angelo Polito6, Bruno Laviolle3,4, Eric Bellissant3,4, Djillali Annane1,2, Jean-Claude Alvarez2,5.   

Abstract

AIM: The combination of hydrocortisone and fludrocortisone improved outcomes in septic shock. However, the specific role of fludrocortisone remains controversial and its pharmacokinetics (PK) has never been investigated in septic shock. This study aimed at characterizing the PK of fludrocortisone in septic shock.
METHODS: This was a single-centre ancillary PK study of a large multinational trial of crystalloids versus colloids for acute hypovolemia in intensive care unit (ICU) patients. In 21 adults with septic shock, fludrocortisone plasma concentrations were measured by liquid chromatography-mass spectrometry tandem analysis, before and repeatedly until 18 h after an oral dose of 50 μg. PK parameters were estimated using a nonlinear mixed-effects modelling.
RESULTS: Undetectable plasma concentrations were observed in 7 out of 21 patients. In the remaining 14 patients, plasma fludrocortisone concentrations were best described by a one-compartmental model with first-order absorption, a lag time (Tlag ) before the absorption phase, and first-order elimination. Severity of illness, as quantified by Simplified Acute Physiology Score II, significantly increased Tlag and apparent clearance. There was a large inter-individual variability in PK parameters. The population estimates of PK parameters (inter-individual variability) were: Tlag 0.65 h (98%), apparent clearance 40 l h-1 (49%) and apparent volume of distribution 78 l (75%). Plasma half-life was estimated at 1.35 h (95% CI, 0.84-2.03) and area under the curve of plasma concentrations was estimated at 1.25 μg h l-1 (95% CI, 1.09-1.46).
CONCLUSIONS: A single oral dose of fludrocortisone yielded undetectable plasma concentrations in one-third of adults with septic shock. Fludrocortisone PK showed a short plasma elimination half-life and a large inter-individual variability.
© 2016 The British Pharmacological Society.

Entities:  

Keywords:  Fludrocortisone; pharmacokinetics; sepsis; shock

Mesh:

Substances:

Year:  2016        PMID: 27416887      PMCID: PMC5099539          DOI: 10.1111/bcp.13065

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  24 in total

1.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

2.  Pharmacokinetics of oral fludrocortisone in septic shock.

Authors:  Andrea Polito; Noureddine Hamitouche; Mégane Ribot; Angelo Polito; Bruno Laviolle; Eric Bellissant; Djillali Annane; Jean-Claude Alvarez
Journal:  Br J Clin Pharmacol       Date:  2016-08-22       Impact factor: 4.335

3.  [Pharmacokinetics of 9 -fluorhydrocortisone].

Authors:  W Vogt; I Fischer; S Ebenroth; S Appel; M Knedel; P W Lücker; H Rennekamp
Journal:  Arzneimittelforschung       Date:  1971-08

4.  The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.

Authors:  Phylinda L S Chan; Philippe Jacqmin; Marc Lavielle; Lynn McFadyen; Barry Weatherley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-11-19       Impact factor: 2.745

5.  A highly sensitive method for the quantification of fludrocortisone in human plasma using ultra-high-performance liquid chromatography tandem mass spectrometry and its pharmacokinetic application.

Authors:  Jagadeesh Banda; Ramalingam Lakshmanan; Shiva Prasad Vvs; Srinibas Patro Gudla; Rosaiah Prudhivi
Journal:  Biomed Chromatogr       Date:  2015-01-22       Impact factor: 1.902

6.  Biological and hemodynamic effects of low doses of fludrocortisone and hydrocortisone, alone or in combination, in healthy volunteers with hypoaldosteronism.

Authors:  B Laviolle; P Le Maguet; M-C Verdier; C Massart; E Donal; F Lainé; A Lavenu; D Pape; E Bellissant
Journal:  Clin Pharmacol Ther       Date:  2010-07-14       Impact factor: 6.875

7.  Human plasma quantification of fludrocortisone using liquid chromatography coupled with atmospheric pressure chemical ionization mass spectrometry after low-dosage administration.

Authors:  Mégane Ribot; Andrea Polito; Stanislas Grassin-Delyle; Djillali Annane; Jean-Claude Alvarez
Journal:  Clin Chim Acta       Date:  2012-12-07       Impact factor: 3.786

8.  Bicarbonate-dependent and bicarbonate-independent mechanisms contribute to nondiffusive uptake of acetate in the ruminal epithelium of sheep.

Authors:  Jörg R Aschenbach; Sabine Bilk; Gebrehiwot Tadesse; Friederike Stumpff; Gotthold Gäbel
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-03-05       Impact factor: 4.052

9.  A sensitive radioimmunoassay for fludrocortisone in human plasma.

Authors:  V P Mitsky; R J Workman; W E Nicholson; J Vernikos; R M Robertson; D Robertson
Journal:  Steroids       Date:  1994-09       Impact factor: 2.668

10.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.

Authors:  R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno
Journal:  Intensive Care Med       Date:  2013-01-30       Impact factor: 17.440

View more
  6 in total

1.  Population Pharmacokinetic-Pharmacodynamic Model of Oral Fludrocortisone and Intravenous Hydrocortisone in Healthy Volunteers.

Authors:  Noureddine Hamitouche; Emmanuelle Comets; Mégane Ribot; Jean-Claude Alvarez; Eric Bellissant; Bruno Laviolle
Journal:  AAPS J       Date:  2017-01-12       Impact factor: 4.009

2.  Pharmacokinetics of oral fludrocortisone in septic shock.

Authors:  Andrea Polito; Noureddine Hamitouche; Mégane Ribot; Angelo Polito; Bruno Laviolle; Eric Bellissant; Djillali Annane; Jean-Claude Alvarez
Journal:  Br J Clin Pharmacol       Date:  2016-08-22       Impact factor: 4.335

3.  Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator.

Authors:  Fredrik Erlandsson; Muna Albayaty; Ligia Chialda; Hans Ericsson; Carl Amilon; Karin Nelander; Rasmus Jansson-Löfmark; Linda Wernevik; Magnus Kjaer; Krister Bamberg; Judith Hartleib-Geschwindner
Journal:  Br J Clin Pharmacol       Date:  2018-04-22       Impact factor: 4.335

Review 4.  CIRMI-a new term for a concept worthy of further exploration: a narrative review.

Authors:  Gladness Dakalo Nethathe; Jeffrey Lipman; Ronald Anderson; Charles Feldman
Journal:  Ann Transl Med       Date:  2022-06

Review 5.  Immune Effects of Corticosteroids in Sepsis.

Authors:  Nicholas Heming; Sivanthiny Sivanandamoorthy; Paris Meng; Rania Bounab; Djillali Annane
Journal:  Front Immunol       Date:  2018-07-30       Impact factor: 7.561

Review 6.  Dysfunction of the hypothalamic-pituitary-adrenal axis in critical illness: a narrative review for emergency physicians.

Authors:  Lucas Oliveira Marino; Heraldo Possolo Souza
Journal:  Eur J Emerg Med       Date:  2020-12       Impact factor: 4.106

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.